[HTML][HTML] Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 …
Background Melanoma brain metastases (MBMs) are a challenging clinical problem with
high morbidity and mortality. Although first-line dabrafenib–trametinib and ipilimumab …
high morbidity and mortality. Although first-line dabrafenib–trametinib and ipilimumab …
Current treatment of melanoma brain metastasis
A Rishi, HHM Yu - Current Treatment Options in Oncology, 2020 - Springer
Opinion statement With greater understanding of underlying biology and development of
effective BRAF-targeted therapy and immunotherapy, along with remarkable advances in …
effective BRAF-targeted therapy and immunotherapy, along with remarkable advances in …
Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies
S Sloot, YA Chen, X Zhao, JL Weber, JJ Benedict… - Cancer, 2018 - Wiley Online Library
BACKGROUND The development of brain metastases is common for systemic treatment
failure in patients with melanoma and has been associated with a poor prognosis. Recent …
failure in patients with melanoma and has been associated with a poor prognosis. Recent …
[HTML][HTML] Long-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo+ ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets) …
Background Preliminary data from the ABC (76 pts, med f/u 17mo) and CheckMate 204 (94
pts, med f/u 14mo) trials showed that nivo and nivo+ ipi have activity in active melanoma …
pts, med f/u 14mo) trials showed that nivo and nivo+ ipi have activity in active melanoma …
Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases.
HM Kluger, SB Goldberg, M Sznol, J Tsiouris… - 2015 - ascopubs.org
9009 Background: Brain metastases (BrMs) develop in 40% of metastatic melanoma (MM)
patients (pts). Untreated BrMs exclude from most clinical trials. In prior trials, treatment of MM …
patients (pts). Untreated BrMs exclude from most clinical trials. In prior trials, treatment of MM …
[HTML][HTML] Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 …
T Amaral, F Kiecker, S Schaefer, H Stege… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Nivolumab combined with ipilimumab have shown activity in melanoma brain
metastasis (MBM). However, in most of the clinical trials investigating immunotherapy in this …
metastasis (MBM). However, in most of the clinical trials investigating immunotherapy in this …
Primary analysis and 4-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases
AM Di Giacomo, V Chiarion-Sileni, M Del Vecchio… - Clinical Cancer …, 2021 - AACR
Purpose: Phase II trials have shown encouraging activity with ipilimumab plus fotemustine
and ipilimumab plus nivolumab in melanoma brain metastases. We report the primary …
and ipilimumab plus nivolumab in melanoma brain metastases. We report the primary …
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
HA Tawbi, PA Forsyth, FS Hodi, CD Lao… - Neuro …, 2021 - academic.oup.com
Background In patients with melanoma and asymptomatic brain metastases (MBM),
nivolumab plus ipilimumab provided an intracranial response rate of 55%. Here, we present …
nivolumab plus ipilimumab provided an intracranial response rate of 55%. Here, we present …
A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with …
M Gonzalez, AM Hong, MS Carlino, V Atkinson… - 2019 - ascopubs.org
TPS9600 Background: Nivolumab combined with ipilimumab is active in melanoma brain
metastases, with intracranial response rates> 55% and durable survival in treatment naïve …
metastases, with intracranial response rates> 55% and durable survival in treatment naïve …
[HTML][HTML] Combined nivolumab and ipilimumab in melanoma metastatic to the brain
HA Tawbi, PA Forsyth, A Algazi, O Hamid… - … England Journal of …, 2018 - Mass Medical Soc
Background Brain metastases are a common cause of disabling neurologic complications
and death in patients with metastatic melanoma. Previous studies of nivolumab combined …
and death in patients with metastatic melanoma. Previous studies of nivolumab combined …
相关搜索
- brain metastases melanoma patients
- ipilimumab nivolumab resistance signature
- braf mek resistance signature
- braf mek ipilimumab nivolumab
- brain metastases combination of nivolumab
- ipilimumab in patients combination of nivolumab
- nivolumab and ipilimumab combined immunotherapy
- nivolumab and ipilimumab local therapy
- brain metastases safety and efficacy
- brain metastases nibit m2
- brain metastases primary analysis
- brain metastases ipilimumab in patients
- patients with melanoma combination of nivolumab
- brain metastases efficacy of the combination